Fiche société
Bristol-Myers Squibb
Traitements, essais et publications liés.
Traitements54programmes
Essais40liés
Publications41liées
SourceDBlocale
Traitements
54| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| BENCHMARK-SLE — A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 ImmunosuppressantsThe purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants | Lupus | À vérifier | À vérifier | United States, Argentina, Brazil, Canada, France, Germany, Israel, Italy, … | À vérifier |
| BMS-986165The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132 | Lupus | Phase 4 | À vérifier | United States | À vérifier |
| BMS-986446The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
| BMS-986504The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion | Cancer | Phase 2/3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Chile, … | À vérifier |
| BMS-986553The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren's disease (SjD). | Lupus, Maladie rénale chronique | Phase 1 | Immunomodulation | United States, Belgium, France, Germany, Netherlands, Poland | À vérifier |
| carboplatinThis phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects. | Cancer, Parkinson, SEP | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| CasdatifanThe purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with other agents in participants with advanced Renal Cell Carcinoma (RCC) | Cancer | Phase 1/2 | À vérifier | United States, Argentina, Australia, Canada, Chile, China, Colombia, Czechia, … | À vérifier |
| CisplatinThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Cancer, Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| danicamtivThe purpose of this Phase 2a study is to establish safety and preliminary efficacy of treatment with danicamtiv in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants or other causalities. | Myopathies | Phase 2 | À vérifier | United States, Germany, Spain, United Kingdom | À vérifier |
| DeucravacitinibThis study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable. | Lupus | Phase 3 | À vérifier | À vérifier | |
| IpilimumabThis phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced), to other places in the body (metastatic) or cannot removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Chemotherapy drugs, such as platinum containing therapies and fluoropyrimidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab alone and in combination with other treatments, including ipilimumab, cabozantinib, platinum containing therapy, or fluoropyrimidine, may be safe, tolerable, and/or effective in treating patients with autoimmune disorders and advanced, metastatic, or unresectable cancer. | Cancer, Lupus, SEP | Phase 1/2 | United States, Argentina, Australia, Canada, Chile, China, Colombia, Czechia, … | À vérifier | |
| Iza-brenA Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy | Cancer | Phase 2/3 | À vérifier | United States, Argentina, Belgium, Canada, Chile, China, Colombia, France, … | À vérifier |
| KarX-ECThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease | Alzheimer | Phase 3 | À vérifier | United States, Argentina, Brazil, Bulgaria, Canada, Chile, China, Croatia, … | À vérifier |
| NivolumabThis phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer. | Cancer, Lupus, Parkinson, SEP | Phase 3 | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier | |
| ORION — A Post-Authorization, Long-term Study of Ozanimod Real-world SafetyThe purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate (S1P) receptor modulator, compared to the rates of these events in two population of participants: * Participants not exposed to ozanimod with RRMS who have received treatment with other S1P-receptor modulators disease modifying treatments (DMTs) * Participants not exposed to ozanimod with RRMS who have received treatment with other non-S1P-receptor modulators disease modifying treatments (DMTs) | SEP | À vérifier | À vérifier | United States | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Cancer, Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PemetrexedThe goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment). | Cancer, Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| RelatlimabThe purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1% | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| Xanomeline Enteric CapsuleThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease. | Alzheimer | Phase 3 | À vérifier | United States, Argentina, Brazil, Bulgaria, Canada, China, Croatia, Greece, … | À vérifier |
| Xanomeline/Trospium Chloride CapsuleThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease. | Alzheimer | Phase 3 | À vérifier | United States, Argentina, Brazil, Bulgaria, Canada, China, Croatia, Greece, … | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Australia, Austria, Canada, Hungary, Italy, Japan, Poland, Portugal, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom | Dispositif/procédure : résultats à interpréter par essai et indication. |
| ORION — A Post-Authorization, Long-term Study of Ozanimod Real-world SafetyThe purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate (S1P) receptor modulator, compared to the rates of these events in two population of participants: * Participants not exposed to ozanimod with RRMS who have received treatment with other S1P-receptor modulators disease modifying treatments (DMTs) * Participants not exposed to ozanimod with RRMS who have received treatment with other non-S1P-receptor modulators disease modifying treatments (DMTs) | SEP | À vérifier | À vérifier | United States | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom | Dispositif/procédure : résultats à interpréter par essai et indication. |
| danicamtivThe purpose of this Phase 2a study is to establish safety and preliminary efficacy of treatment with danicamtiv in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants or other causalities. | Myopathies | Phase 2 | À vérifier | United States, Germany, Spain, United Kingdom | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 1/2 | Ablation tumorale non thermique | United States, Australia, France, Israel, Italy, South Africa, Switzerland | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 2 | Ablation tumorale non thermique | United States, Austria, Canada, Hungary, Israel, Italy, Poland, Russia, South Korea, Spain, Switzerland | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 1/2 | Ablation tumorale non thermique | United States, Brazil, Chile, China, France, Germany, Italy, Norway, South Korea, Switzerland, Taiwan, Thailand | Dispositif/procédure : résultats à interpréter par essai et indication. |
| Xanomeline/Trospium Chloride CapsuleThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease. | Alzheimer | Phase 3 | À vérifier | United States, Argentina, Brazil, Bulgaria, Canada, China, Croatia, Greece, India, Japan, Mexico, Portugal, Romania, Spain, Taiwan | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Australia, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Guatemala, Hungary, Ireland, Italy, Japan, Malaysia, Mexico, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| carboplatinThis phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Cancer | Phase 2 | Ablation tumorale non thermique | Brazil | Dispositif/procédure : résultats à interpréter par essai et indication. |
| BENCHMARK-SLE — A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 ImmunosuppressantsThe purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants | Lupus | À vérifier | À vérifier | United States, Argentina, Brazil, Canada, France, Germany, Israel, Italy, Japan, Puerto Rico, Spain, Sweden, United Kingdom | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Australia, Brazil, Chile, China, France, Germany, Guatemala, Ireland, Israel, Italy, Japan, New Zealand, Poland, Russia, South Korea, Spain, Turkey (Türkiye), Ukraine, United Kingdom | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 1/2 | Ablation tumorale non thermique | United States, Canada, Hungary, Israel, Italy, Poland, South Korea, Spain, Taiwan, Ukraine | Dispositif/procédure : résultats à interpréter par essai et indication. |
| Xanomeline/Trospium Chloride CapsuleThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease. | Alzheimer | Phase 3 | À vérifier | United States, Argentina, Chile, Czechia, France, Germany, Hungary, Israel, Italy, Poland, Puerto Rico, South Korea, Ukraine, United Kingdom | À vérifier |
| DeucravacitinibThis study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable. | Lupus | Phase 3 | À vérifier | À vérifier | |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Cancer | Phase 3 | Ablation tumorale non thermique | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Malaysia, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| BMS-986165The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132 | Lupus | Phase 4 | À vérifier | United States | À vérifier |
| carboplatinThis phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 2 | Ablation tumorale non thermique | United States, Canada, Chile, Colombia, France, Germany, Hungary, Ireland, Japan, Poland, South Korea, Spain, Taiwan, Ukraine, United Kingdom | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Argentina, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Mexico, Norway, Poland, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 1/2 | Ablation tumorale non thermique | United States, Australia, Canada, Chile, Colombia, France, Hungary, Israel, Netherlands, New Zealand, Poland, South Korea, Spain, United Kingdom | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 1/2 | Ablation tumorale non thermique | United States, Australia, Canada, Chile, France, Hungary, Israel, Netherlands, New Zealand, Poland, South Korea, Spain, United Kingdom | Dispositif/procédure : résultats à interpréter par essai et indication. |
| BMS-986446The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Australia, Belgium, Canada, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Mexico, Poland, Russia, South Korea, Spain, Sweden, Thailand, Turkey (Türkiye), … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| Iza-brenA Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy | Cancer | Phase 2/3 | À vérifier | United States, Argentina, Belgium, Canada, Chile, China, Colombia, France, Germany, Greece, India, Italy, Japan, Mexico, Netherlands, Norway, Poland, Romania, Singapore, South Korea, … | À vérifier |
| BMS-986553The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren's disease (SjD). | Maladie rénale chronique | Phase 1 | Immunomodulation | United States, Belgium, France, Germany, Netherlands, Poland | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Costa Rica, Finland, France, Germany, Greece, Guatemala, Hungary, Italy, Japan, Malaysia, Netherlands, Norway, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| NivolumabThis phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer. | Cancer | Phase 3 | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, France, Germany, India, Ireland, Italy, Japan, Mexico, Netherlands, New Zealand, … | À vérifier | |
| BMS-986504The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion | Cancer | Phase 2/3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, … | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Argentina, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Estonia, France, Germany, Guatemala, Hong Kong, Hungary, Italy, Japan, Mexico, Peru, Philippines, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
Essais cliniques
40| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Pembrolizumab | Parkinson | Phase 3 | NCT04210115 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | COMPLETED |
| BMS-986504 | Cancer | Phase 2/3 | NCT07063745 | MountainTAP-29 — A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | RECRUITING |
| Nivolumab | Cancer | Phase 3 | NCT06561386 | RELATIVITY1093 — A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | RECRUITING |
| Pumitamig | Cancer | Phase 1/2 | NCT07293351 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT03711032 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | ACTIVE_NOT_RECRUITING |
| BMS-986553 | Maladie rénale chronique | Phase 1 | NCT07873931 | A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases | NOT_YET_RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT06937229 | A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | RECRUITING |
| Iza-bren | Cancer | Phase 2/3 | NCT07100080 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT03924856 | Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) | COMPLETED |
| BMS-986446 | Alzheimer | Phase 1 | NCT07780383 | A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration | RECRUITING |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT04626518 | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | COMPLETED |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT04626479 | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | COMPLETED |
| Pembrolizumab | Parkinson | Phase 3 | NCT04634877 | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | ACTIVE_NOT_RECRUITING |
| Pembrolizumab | Parkinson | Phase 2 | NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | TERMINATED |
| carboplatin | Cancer | Phase 2 | NCT04665765 | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING |
| BMS-986165 | Lupus | Phase 4 | NCT06875960 | A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 | RECRUITING |
| Pembrolizumab | Cancer | Phase 3 | NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | RECRUITING |
| Ozanimod | SEP | Phase 3 | NCT06408259 | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis | RECRUITING |
| Deucravacitinib | Lupus | Phase 3 | NCT07791199 | Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers | NOT_YET_RECRUITING |
| Xanomeline/Trospium Chloride Capsule | Alzheimer | Phase 3 | NCT07011745 | A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease | RECRUITING |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT04165070 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT03615326 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | COMPLETED |
| BENCHMARK-SLE — A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants | Lupus | À vérifier | NCT07175285 | BENCHMARK-SLE — A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants | RECRUITING |
| Ozanimod | SEP | À vérifier | NCT07732907 | Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia | RECRUITING |
| Pembrolizumab | Cancer | Phase 2 | NCT06822543 | TROPICAL-1 — A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) | RECRUITING |
| carboplatin | Cancer | Phase 2 | NCT06890338 | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT04736706 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) | ACTIVE_NOT_RECRUITING |
| Afimetoran | Lupus | Phase 2 | NCT04895696 | A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | ACTIVE_NOT_RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT07216703 | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) | RECRUITING |
| Xanomeline/Trospium Chloride Capsule | Alzheimer | Phase 3 | NCT07011732 | A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) | RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT06976203 | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT06469944 | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT06623422 | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 2 | NCT04924101 | Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) | COMPLETED |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT04305041 | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | COMPLETED |
| danicamtiv | Myopathies | Phase 2 | NCT04572893 | Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities | TERMINATED |
| Pembrolizumab | Parkinson | Phase 3 | NCT03898180 | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | COMPLETED |
| ORION — A Post-Authorization, Long-term Study of Ozanimod Real-world Safety | SEP | À vérifier | NCT05605782 | ORION — A Post-Authorization, Long-term Study of Ozanimod Real-world Safety | ACTIVE_NOT_RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT03358472 | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | COMPLETED |
Publications
41| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| danicamtiv | Danicamtiv increases cardiac mechanical efficiency. | The Journal of physiology | ||
| Ipilimumab | Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond. | International journal of cancer | ||
| Ipilimumab | Automated volumetric iRECIST-inspired CT assessment of treatment response to dual immune checkpoint inhibition in metastatic renal cell carcinoma: A feasibility study. | European journal of radiology | ||
| Ipilimumab | Tailored management of a melanoma patient with bleeding brain metastases and deep vein thrombosis with thrombectomy. | CNS oncology | ||
| Nivolumab | Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies. | Oncoimmunology | ||
| Pemetrexed | Pemetrexed potentiates γδ T cell-based immunotherapy in NSCLC through ATM-STING-NF-κB-mediated induction of NKG2D ligands. | International immunopharmacology | ||
| Pemetrexed | Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer. | Journal of medical economics | ||
| Pemetrexed | Implications of formulation change on the in-use stability of compounded pemetrexed infusion bags: Impact of excipients, solvent and storage conditions. | Journal of pharmaceutical and biomedical analysis | ||
| Cisplatin | Bis-(di-4-phenyl-benzylaminethiocarbonyl)disulfide sensitizes ABCC2/ALDH3A1 overexpressing NSCLC cells to cisplatin. | Cancer biology & therapy | ||
| Pembrolizumab | Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC). | Oncoimmunology | ||
| carboplatin | Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids. | Cancer biology & therapy | ||
| carboplatin | A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma. | Oncoimmunology | ||
| carboplatin | Leverage of quick-soluble gelatin microparticles in transarterial chemoembolization of canine urothelial carcinomas. | The veterinary quarterly | ||
| danicamtiv | Cardiac Myosin Activators in Heart Failure: Experimental Advances Amid Clinical Uncertainty. | Drug design, development and therapy | ||
| danicamtiv | The role of cardiac myosin activators in dilated cardiomyopathy pharmacotherapy. | Expert opinion on pharmacotherapy | ||
| Ipilimumab | Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis. | International journal of clinical oncology | ||
| Ipilimumab | Dual versus single-agent immune checkpoint inhibitor therapy in microsatellite instability-high metastatic colorectal cancer: an analysis based on reconstructed patient data. | ESMO gastrointestinal oncology | ||
| Nivolumab | Biomarkers of nivolumab benefit in resectable non-small cell lung cancer. | Nature | ||
| Pemetrexed | Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. | JAMA | ||
| Pemetrexed | Lack of resolution of inflammation marks malignant pleural mesothelioma progression. | Cancer drug resistance (Alhambra, Calif.) | ||
| Cisplatin | PKM2 Inhibitors Induce Autophagic Cell Death Through Suppression of PKM2-Mediated Glycolysis in Cisplatin-Resistant Ovarian Cancer Cells. | International journal of molecular sciences | ||
| Pembrolizumab | Immunotherapy in the Treatment of Soft Tissue Sarcoma Since SARC028: An NCDB Analysis. | Journal of surgical oncology | ||
| carboplatin | Repurposing Alzheimer's and ovarian cancer drugs as sonosensitizers for glioblastoma via a positive-unlabeled learning and 3D bioprinting-based new approach methodology (NAM). | PloS one | ||
| carboplatin | Sequential development of isolated ACTH deficiency and fulminant type 1 diabetes as delayed immune-related endocrine adverse events. | BMJ case reports | ||
| Cisplatin | Multidisciplinary treatment with conversion surgery after radiological complete response of liver metastasis to gemcitabine, cisplatin, and durvalumab in metastatic distal cholangiocarcinoma. | Clinical journal of gastroenterology | ||
| Cisplatin | Author Reply to Letter to the Editor Regarding "Intratympanic Dexamethasone Efficacy in Preventing Cisplatin-Induced Tinnitus: A Randomized Controlled Phase IIIB Clinical Trial". | Ear and hearing | ||
| Pembrolizumab | Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland. | Journal of medical economics | ||
| Pembrolizumab | C-reactive protein at pembrolizumab initiation and its trajectory from first-line chemotherapy as prognostic markers in metastatic urothelial carcinoma (YUSHIMA study). | International urology and nephrology | ||
| carboplatin | Drug-Induced liver injury with adebrelimab: how to assess causality using the updated RUCAM? | Future science OA | ||
| carboplatin | DUSP5 contributes to platinum resistance in ovarian cancer: single-cell discovery and functional validation. | Frontiers in pharmacology | ||
| carboplatin | An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal. | Expert review of anticancer therapy | ||
| carboplatin | Exploding retinoblastoma- Management of spontaneous scleral rupture in an infant with bilateral retinoblastoma. | Retinal cases & brief reports | ||
| carboplatin | Performance status 2 or higher in EMA labels for advanced non-small-cell lung cancer: a cross-sectional SmPC analysis. | Cancer treatment and research communications | ||
| carboplatin | Integrated Network Pharmacology and Proteomics Reveal Anti-tumor Mechanism of Securinine in Ovarian Cancer. | Chinese journal of integrative medicine | ||
| carboplatin | Efficacy of poloxamer Р188 in restoring the metabolic profile in myelosuppression: a non-invasive nuclear magnetic resonance spectroscopy study. | Biomeditsinskaia khimiia | ||
| carboplatin | Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer. | JAMA network open | ||
| carboplatin | Primary Small Cell Neuroendocrine Carcinoma of the Breast in a 75-Year-Old Woman With Aggressive Recurrence Despite Multimodal Therapy: A Case Report and Literature Review. | The American journal of case reports | ||
| carboplatin | Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | ||
| carboplatin | Acute Appendicitis at Stem Cell Infusion During Autologous Transplantation for HIV-Associated Diffuse Large B-cell Lymphoma: A Case Report. | Cureus | ||
| carboplatin | Severe Inflammatory Cystitis and Ureteritis Following Neoadjuvant TCHP (Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab) Therapy in HER2-Positive Breast Cancer: A Case Report and Literature Review. | Cureus | ||
| carboplatin | Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320). | JAMA oncology |